LTRN
Lantern Pharma Inc

1,427
Loading...
Loading...
News
all
press releases
Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and...
Business Wire·7mo ago
News Placeholder
More News
News Placeholder
Lantern Pharma Announces First Patient Enrolled in Taiwan for Phase 2 HARMONIC Clinical Trial of LP-300 in Never-Smoker NSCLC Patients
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR AI platform, today announced that the first patient has...
Business Wire·9mo ago
News Placeholder
Lantern Pharma and Starlight Therapeutics Present LP-184 (STAR-001) Phase 1b Trial Design and Preclinical Data in Glioblastoma at Society for Neuro-Oncology (SNO) 2024 Highlighting Novel Synthetic Lethality
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence company transforming oncology drug development, and its wholly-owned subsidiary Starlight Therapeutics, focused exclusively on CNS and...
Business Wire·10mo ago
News Placeholder
Lantern Pharma Announces First Patient Dosed in Japan for The Expansion Cohort in The Phase 2 HARMONIC Clinical Trial of LP-300 in Never-Smoker NSCLC Patients
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR AI platform, today announced that the first patient has...
Business Wire·10mo ago
News Placeholder
Lantern Pharma Reports Third Quarter 2024 Financial Results and Business Updates
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (ML) platform...
Business Wire·10mo ago
News Placeholder
Starlight Therapeutics Announces Inaugural Members of Scientific Advisory Board
Starlight Therapeutics, a wholly-owned subsidiary of Lantern Pharmaceuticals (NASDAQ: LTRN), formed to develop transformative CNS cancer treatments with AI-powered innovation, announced today the...
Business Wire·10mo ago
News Placeholder
Lantern Pharma to Report Third Quarter 2024 Operating & Financial Results on November 7th, 2024 at 4:30 p.m. ET
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (ML) platform...
Business Wire·10mo ago
News Placeholder
Lantern Pharma to Present at the ThinkEquity Conference in NYC on October 30, 2024
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and...
Business Wire·11mo ago
News Placeholder
Lantern Pharma to Host & Participate in Two Public Webinars During October
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and...
Business Wire·11mo ago
News Placeholder
Lantern Pharmas Investigational Drug-Candidate, LP-184, Receives Fast-Track Designation in Glioblastoma from the FDA
Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company dedicated to developing cancer therapies and transforming the cost, pace, and timeline of oncology drug discovery and...
Business Wire·11mo ago

Latest LTRN News

View

Advertisement. Remove ads.

Advertisement. Remove ads.

Advertisement. Remove ads.